Sorafenib: a review of its use in advanced hepatocellular carcinoma

GM Keating, A Santoro - Drugs, 2009 - Springer
Sorafenib (Nexavar®) is an orally active multikinase inhibitor that is approved in the EU for
the treatment of hepatocellular carcinoma. Monotherapy with sorafenib prolongs overall …
被引用次数：610 相关文章

Sorafenib: A Review of its Use in Advanced Hepatocellular Carcinoma

GM Keating, A Santoro - Drugs, 2009 - search.proquest.com
Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved in the EU for the
treatment of hepatocellular carcinoma. Monotherapy with sorafenib prolongs overall survival …

[引用][C] Sorafenib: A Review of its Use in Advanced Hepatocellular Carcinoma

GM KEATING, A SANTORO - Drugs (Basel), 2009 - pascal-francis.inist.fr
Sorafenib : A Review of its Use in Advanced Hepatocellular Carcinoma CNRS Inist Pascal-Francis
CNRS Pascal and Francis Bibliographic Databases Simple search Advanced search Search by …

Sorafenib: A Review of its Use in Advanced Hepatocellular Carcinoma.

GM Keating, A Santoro - Drugs, 2009 - search.ebscohost.com
Sorafenib (Nexavar®) is an orally active multikinase inhibitor that is approved in the EU for
the treatment of hepatocellular carcinoma. Monotherapy with sorafenib prolongs overall …

[引用][C] Sorafenib: a review of its use in advanced hepatocellular carcinoma

K GM - Drugs, 2009 - cir.nii.ac.jp

Sorafenib A Review of its Use in Advanced Hepatocellular Carcinoma

GM Keating, A Santoro - Drugs, 2009 - hero.epa.gov
Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved in the EU for the
treatment of hepatocellular carcinoma. Monotherapy with sorafenib prolongs overall survival …

Sorafenib: a review of its use in advanced hepatocellular carcinoma

GM Keating, A Santoro - Drugs, 2009 - pubmed.ncbi.nlm.nih.gov
Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved in the EU for the
treatment of hepatocellular carcinoma. Monotherapy with sorafenib prolongs overall survival …

Sorafenib: a review of its use in advanced hepatocellular carcinoma.

GM Keating, A Santoro - Drugs, 2009 - europepmc.org
Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved in the EU for the
treatment of hepatocellular carcinoma. Monotherapy with sorafenib prolongs overall survival …

Sorafenib: a review of its use in advanced hepatocellular carcinoma

GM Keating, A Santoro - Drugs, 2009 - go.gale.com
Sorafenib (Nexavar [R]) is an orally active multikinase inhibitor that is approved in the EU for
the treatment of hepatocellular carcinoma. Monotherapy with sorafenib prolongs overall …

[引用][C] Sorafenib

GM Keating, A Santoro - Drugs, 2009 - cir.nii.ac.jp
Sorafenib | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索
フォームへ移動 論文・データをさがす 大学図書館の本をさがす 日本の博士論文をさがす English 検索 …